Literature DB >> 24495700

Geriatric screening results and the association with severe treatment toxicity after the first cycle of (radio)chemotherapy.

Abdelbari Baitar1, Frank Van Fraeyenhove2, An Vandebroek2, Els De Droogh3, Daniella Galdermans3, Jeroen Mebis4, Dirk Schrijvers2.   

Abstract

BACKGROUND: Screening tools are used in geriatric oncology to determine who should receive a Comprehensive Geriatric Assessment (CGA). However, in this prospective study, we evaluated the association between geriatric screening results, measured with the G8 and Groningen Frailty Indicator (GFI), and severe treatment toxicity.
METHODS: Patients over 65 years with various types and stages of cancer were screened with the G8 and the GFI prior to the start of treatment. The association between geriatric screening results and Serious Adverse Events (SAE) after the first cycle of (radio)chemotherapy were studied with bivariate analysis (normal versus abnormal screening test) and logistic regression analysis.
RESULTS: From 170 screened patients, 85 patients were eligible for this study. The median age was 76 years (range: 66-88 years). The treatment intent was curative in 46% and palliative in 54%. A SAE occurred in 15 patients (18%) of which three resulted in death. There was no significant association between the G8, as a dichotomous predictor (p = 0.376) or as a continuous predictor (p = 0.298), and risk of a SAE. We also found no significant association for the GFI analysed as a dichotomous predictor (cut-off ≥4: p = 0.384; cut-off ≥3: p = 0.773), nor as a continuous predictor (p = 0.734). All associations remained insignificant when adjusted for treatment type and comorbidity.
CONCLUSION: The G8 and the GFI can be used to select patients for CGA, but they do not seem to be predictive for short-term severe treatment toxicity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy toxicity; G8; Geriatric screening; Groningen frailty indicator

Mesh:

Substances:

Year:  2014        PMID: 24495700     DOI: 10.1016/j.jgo.2013.12.004

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  6 in total

1.  Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age.

Authors:  Jimmy Ruiz; Antonius A Miller; Janet A Tooze; Sandrine Crane; William J Petty; Ajeet Gajra; Heidi D Klepin
Journal:  J Geriatr Oncol       Date:  2018-07-10       Impact factor: 3.599

Review 2.  How should older adults with cancer be evaluated for frailty?

Authors:  Megan Huisingh-Scheetz; Jeremy Walston
Journal:  J Geriatr Oncol       Date:  2016-06-16       Impact factor: 3.599

3.  Performance of two frailty screening tools among patients with cancer in Taiwan.

Authors:  Shih-Ying Chen; Wen-Chi Chou; Yung-Chang Lin; Ngan-Ming Tsang; Kuo-Chen Liao; Chung-Hao Lin; Jr-Rung Lin; Ya-Wen Ho; Woung-Ru Tang
Journal:  Biomed J       Date:  2021-03-10       Impact factor: 7.892

4.  Frailty and checkpoint inhibitor toxicity in older patients with melanoma.

Authors:  Cheryl P Bruijnen; José J Koldenhof; Rik J Verheijden; Frederiek van den Bos; Mariëlle H Emmelot-Vonk; Petronella O Witteveen; Karijn P M Suijkerbuijk
Journal:  Cancer       Date:  2022-04-19       Impact factor: 6.921

Review 5.  Instruments That Predict Oncology Treatment Risk in the Senior Population.

Authors:  Jessica K Schiefen; Lydia T Madsen; Joyce E Dains
Journal:  J Adv Pract Oncol       Date:  2017-07-01

6.  Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians).

Authors:  Carsten Nieder; Thomas A Kämpe
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2017-01-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.